Revvity ($RVTY) Stock Forecast: Up 5.0% Today

What is Revvity?

Revvity (RVTY) is a company specializing in integrated cancer research solutions, with a focus on showcasing its latest innovations at the AACR Annual Meeting 2026. The company is dedicated to advancing discoveries in oncology research through advanced imaging systems, AI software, and reagents. Additionally, Revvity plans to present at upcoming investor conferences to offer insights into its strategic priorities.

Why is Revvity going up?

RVTY stock is up 5.0% on Apr 17, 2026 19:43

• The bullish movement in Revvity's stock today is linked to the positive reception of its integrated cancer research solutions unveiled at the AACR Annual Meeting 2026, demonstrating the company's dedication to enhancing oncology research and patient outcomes.
• Investor optimism and interest in the stock have been fueled by the anticipation surrounding Revvity's upcoming earnings report, notably following the introduction of Signals BioDesign, a cloud-native molecular cloning platform.
• Despite recent downgrades by Barclays to an "equal weight" rating, Revvity's impressive Q4 earnings performance and strong FY2026 guidance have reinforced confidence in the company's growth prospects, contributing to the positive market movement observed today.

RVTY Price Chart

RVTY Technical Analysis

RVTY News

Revvity Showcases Integrated Cancer Research Solutions at AACR Annual Meeting 2026

Revvity is showcasing its latest integrated cancer research solutions at the AACR Annual Meeting 2026, held in San Diego from April 17-22. The company's comprehensive suite of research-use-only oncology solutions, including advanced imaging systems, AI software, and reagents, aims to accelerate discoveries from preclinical to translational research. These innovations are designed to streamline workflows, reduce variability, and empower scientists with AI-driven insights to achieve better patient outcomes.

https://www.pharmiweb.com/press-release/2026-04-16/revvity-showcases-integrated-cancer-research-solutions-at-aacr-annual-meeting-2026

Revvity Showcases Integrated Cancer Research Solutions at AACR Annual Meeting 2026

Revvity, Inc. is showcasing its latest integrated cancer research solutions at the AACR Annual Meeting 2026, offering a comprehensive suite of tools from sample preparation to data analysis. These solutions leverage AI-driven insights and advanced technologies to accelerate discoveries and improve patient outcomes. The company highlights products like the Opera Phenix™ OptIQ system and Living Image™ Synergy AI software, aiming to empower researchers with end-to-end workflows.

https://www.businesswire.com/news/home/20260416903856/en/Revvity-Showcases-Integrated-Cancer-Research-Solutions-at-AACR-Annual-Meeting-2026

Revvity to Present at Upcoming Investor Conferences

Revvity, Inc. (NYSE: RVTY) announced it will present at the BofA Securities 2026 Health Care Conference on May 13, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Company representatives, including senior vice president Steve Willoughby and CEO Prahlad Singh, will provide updates on the company and its strategic priorities. Live webcasts and replays of the presentations will be available on Revvity's Investor Relations website.

https://www.businesswire.com/news/home/20260416523258/en/Revvity-to-Present-at-Upcoming-Investor-Conferences

Assessing Revvity (RVTY) Valuation After Signals BioDesign Launch And Earnings Anticipation

Revvity (RVTY) recently launched Signals BioDesign, a cloud-native molecular cloning platform, drawing investor attention ahead of its upcoming earnings report. Despite short-term gains, the stock has seen longer-term declines in total shareholder returns over one and three years. Analysts currently deem Revvity undervalued, with a fair value of $119.56, suggesting potential for margin expansion, though its high P/E ratio raises questions about market overpayment for recovery.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/assessing-revvity-rvty-valuation-after-signals-biodesign-lau

Revvity (NYSE:RVTY) Lowered to Equal Weight Rating by Barclays

Barclays downgraded Revvity (NYSE:RVTY) from "overweight" to "equal weight" and set a $95 price target, indicating a modest potential upside. Despite the downgrade, Revvity recently exceeded Q4 earnings expectations with $1.70 EPS and $772.1M revenue, also providing strong FY2026 guidance. Analyst sentiment is mixed, with the stock currently holding an average rating of "Hold" and a consensus price target of $110.17.

https://www.marketbeat.com/instant-alerts/revvity-nyservty-lowered-to-equal-weight-rating-by-barclays-2026-04-15/

Trending Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Down 5.2% Today

BlackLine, Inc. ($BL) Stock Forecast: Down 5.7% Today

Lucid Motors Inc. ($LCID) Stock Forecast: Down 5.4% Today

Analog Devices Inc. ($ADI) Stock Forecast: Up 5.1% Today

Marathon Petroleum Corporation ($MPC) Stock Forecast: Down 5.8% Today

Revvity ($RVTY) Stock Forecast: Up 5.0% Today

Ralph Lauren Corporation ($RL) Stock Forecast: Up 5.6% Today

Albemarle Corporation ($ALB) Stock Forecast: Down 6.1% Today

Expedia Group Inc. ($EXPE) Stock Forecast: Up 5.1% Today

Harley-Davidson Inc. ($HOG) Stock Forecast: Up 5.2% Today

Revvity Price History

22.00.2026 - RVTY Stock was up 5.3%

• Today's positive movement in Revvity can be linked to the optimistic investor sentiment driven by the company's robust financial performance and strategic partnerships.
• The partnership announcement with Eli Lilly to incorporate AI models into Revvity Signals platform likely bolstered investor trust in the company's future growth possibilities.
• The acquisition of a significant stake by Campbell & CO Investment Adviser LLC and Revvity's sanctioned share buyback program reflect confidence from institutional investors and the company itself.
• The recently finalized $650 million sale of Avantor's clinical services business to Revvity may have also played a part in the positive trend, highlighting Revvity's tactical expansion and potential for increased revenue.

12.01.2026 - RVTY Stock was down 7.6%

• Despite introducing new automation platforms, such as the Opera Phenix OptIQ system and EnVision Nexus One plate reader, at a recent industry event, Revvity's stock faced a bearish trend.
• The company's valuation being 27.4% below estimated fair value and a share price 15% below analyst targets might have contributed to the negative market movement.
• Investors are advised to closely monitor the adoption of these new platforms, their impact on revenue growth, and any adjustments to analyst forecasts to gauge the stock's future performance accurately.

12.01.2026 - RVTY Stock was down 5.2%

• Revvity's launch of innovative high-throughput discovery and automation platforms at SLAS2026 is intended to meet the need for quicker experiments and streamlined processes in labs, potentially driving recurring revenue.
• However, despite these advancements, the stock's downward trend may be attributed to concerns surrounding the company's diminishing 1, 3, and 5-year returns, alongside its valuation falling below projected fair value and analyst estimations.
• Investors' response to existing risks associated with Revvity, like its relatively high P/E ratio and highlighted concerns about one-time items impacting reported earnings, likely contributed to today's bearish market performance.

06.02.2026 - RVTY Stock was down 5.1%

• Revvity's stock exhibited a downward trend today, influenced by general market uncertainties and concerns regarding its capital allocation strategies.
• The unexpected decline in healthcare employment noted in the February jobs report has raised apprehensions about diminishing healthcare expenditure and demand, affecting companies in the healthcare sector like Revvity.
• Interrogations regarding Revvity's conservative 2026 outlook and capital allocation methods have prompted investors to reassess the company's prospects for growth, resulting in a downturn in the stock price.
• Despite the immediate hurdles, Revvity's strong array of products and ability to generate cash indicate that holding onto the stock in investment portfolios could be logical for long-term investors interested in its growth potential.

06.02.2026 - RVTY Stock was down 6.5%

• Revvity's stock has experienced bearish trends due to caution in the 2026 forecasts and investor apprehensions about capital allocation.
• Despite positive earnings and a promising FY2026 outlook, investor focus on capital management and its implications on future growth has overshadowed the company's strong fundamentals.
• Changes in Citigroup Inc.'s stake and increased institutional ownership indicate a mix of investor sentiments toward Revvity, contributing to the downward movement in stock value.
• The downward trajectory in Revvity's stock price today is attributed to market uncertainties regarding the company's capital allocation strategy and its potential impact on growth, shaping the prevailing bearish sentiment.

03.01.2026 - RVTY Stock was up 1.5%

• Analysts from several firms, such as TD Cowen, Evercore ISI Group, Wells Fargo, and KeyBanc, have increased their price targets for Revvity stock, indicating a favorable outlook for the company.
• The company's impressive Q4 performance, surpassing adjusted earnings expectations and providing a positive fiscal 2026 outlook, has led to the heightened price targets and ratings.
• Revvity's board approving a $1.0 billion share buyback program has also influenced analysts' recommendations and contributed to the upward movement in the stock.
• The optimistic future outlook, strong financial results, and positive analyst assessments have collectively driven the bullish trend for Revvity (RVTY) stock.

03.01.2026 - RVTY Stock was down 5.3%

• An analyst raised Revvity's price target to $124 from $120, reflecting a 15% premium over the current share price, but the stock saw a pre-market decline, possibly leading to profit-taking by investors.
• Despite positive momentum indicators and analyst upgrades, including from another firm, the market movement could be influenced by broader market trends or sector-specific challenges impacting investor sentiment.
• The strong Q4 results and optimistic fiscal 2026 outlook may have already been priced into the stock, leading to a sell-off after the earnings announcement as investors locked in gains.
• Overall, the bearish movement in Revvity's stock today could be a result of a combination of profit-taking, market dynamics, and potential overvaluation following the recent price target upgrades and positive analyst forecasts.

17.03.2026 - RVTY Stock was up 5.0%

• The bullish movement in Revvity's stock today is linked to the positive reception of its integrated cancer research solutions unveiled at the AACR Annual Meeting 2026, demonstrating the company's dedication to enhancing oncology research and patient outcomes.
• Investor optimism and interest in the stock have been fueled by the anticipation surrounding Revvity's upcoming earnings report, notably following the introduction of Signals BioDesign, a cloud-native molecular cloning platform.
• Despite recent downgrades by Barclays to an "equal weight" rating, Revvity's impressive Q4 earnings performance and strong FY2026 guidance have reinforced confidence in the company's growth prospects, contributing to the positive market movement observed today.

04.02.2026 - RVTY Stock was up 5.3%

• The positive performance of Revvity Inc. ($RVTY) today is correlated with its robust quarterly earnings results and optimistic future guidance.
• Despite recent challenges in share price and competition, the encouraging earnings report and positive outlook have instilled confidence among investors, leading to an upward trend in the stock.
• The increased interest from notable institutional investors, like Mitsubishi UFJ Asset Management Co. Ltd., reflects confidence in Revvity's future, contributing to its stock price increase.
• Different methods of valuation present varying perspectives, with DCF models indicating undervaluation and P/E ratios suggesting overvaluation. This disparity may have caused some fluctuations, but investors continue to capitalize on the positive earnings momentum.

14.03.2026 - RVTY Stock was up 5.0%

• Revvity was downgraded by Barclays from Overweight to Equalweight, accompanied by a lowered price target, signaling a more cautious stance on the stock's trajectory.
• Despite positive Q1 2026 earnings expectations and consistent outperformance relative to Wall Street predictions, apprehensions regarding new international trade policies have caused Revvity's stock to diminish in value over the past year.
• The launch of Signals BioDesign underscores Revvity's strategic initiative to enhance molecular cloning and R&D data processing, addressing crucial requirements in biologics research, which could fuel long-term expansion despite recent stock fluctuations.
• Price target modifications by financial entities like Goldman Sachs and TD Cowen, combined with Revvity's underperformance compared to broader market benchmarks, are factors contributing to the varied outlook on the company's stock performance.

12.02.2026 - RVTY Stock was down 5.2%

• A notable institution, Barclays PLC, decreased its stake in Revvity by 11.5%, potentially reflecting concerns about the company's future prospects and influencing the bearish market movement.
• Conversely, Neuberger Berman Group LLC notably augmented its holdings in Revvity, indicating varying sentiments among institutional investors about the stock's potential.
• Investor enthusiasm for Revvity may have been tempered by a Bretton Fund letter cautioning about the 2026 outlook and scrutinizing capital allocation, potentially contributing to the downward trend.
• The unexpected decline in nonfarm payroll jobs, affecting the healthcare sector and Revvity among others, intensified market uncertainty and contributed to the stock's overall decline.

14.00.2026 - RVTY Stock was up 5.1%

• Following the release of upbeat Q4 earnings forecasts, Revvity's stock experienced a notable surge, underlining robust revenue expansion.
• Market analysts have backed the stock with a "Buy" recommendation, setting an average price target of $120.24, which has heightened investor confidence in the company's trajectory.
• While concerns surrounding the stock's potential overvaluation based on the P/E ratio have surfaced, the positive anticipated financial performance and optimistic 2026 outlook have eclipsed these reservations, propelling the bullish market sentiment.
• The upcoming earnings call and the CEO's presentation at the J.P. Morgan Healthcare Conference are poised to offer additional insights into Revvity's financial standing and future growth prospects, potentially sustaining the positive momentum surrounding the stock.